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ABSTRACT
Hot melt extrusion (HME) was evaluated as a continuous processing technology for the
manufacture of solid dispersions. The aim of the current research project was to study the effect
of pressurized carbon dioxide (P-CO2) on the physico-mechanical properties of three different
grades of cellulose polymers, Klucel™ ELF, EF and LF hydroxypropylcellulose (HPC) resulting
from hot melt extrusion techniques, and to assess the plasticization effect of P-CO2 on the tested
polymers. The physico-mechanical properties as well as the tablet characteristics of the
extrudates with and without injection of P-CO2 and with non-extruded polymers were examined.
P-CO2 acted as plasticizer for Klucel™ LF, EF and ELF and allowed for a reduction in
processing temperature during the extrusion process by 20°C as compared to the processing
temperature without injecting P-CO2. Furthermore, the CO2 served as a pore former and
produced foam-like structure extrudates. This morphological change resulted in an increase in
bulk and tap density as well as surface area and porosity. Additionally, the hardness of the tablets
of the polymers with P-CO2 was increased compared to polymer processed without P-CO2 and
the non-extruded polymer. Moreover, the % friability of the tablets improved using P-CO2
processed polymer. Thus good binding properties and compressibility of the extrudates were
positively influenced utilizing P-CO2 processing.
The interest to incorporate a model was increased to investigate the effect of pressurized
carbon dioxide (P-CO2) on the physico-mechanical properties as well as the drug release
behavior.

ii

Ketoprofen (KTP), used as a model drug, was incorporated with hydroxypropylcellulose
(HPC) (Klucel™ ELF, EF and LF) as a polymeric carrier to produce KTP amorphous solid
dispersion using HME technique. Thermal gravimetric analysis (TGA) was used to evaluate and
confirm the formulations thermal stability. Differential Scanning Calorimetery (DSC) was
performed to evaluate the physical state of KTP in the extrudates. The microscopic morphology
of the extrudates was changed to a foam-like structure due to expansion of the CO2 at the
extrusion die. The foamy extrudates demonstrated enhanced KTP release compared to the
extrudates processed without P-CO2 due to the increase in porosity and surface area of those
extrudates. The moisture content of the extrudates processed with P-CO2 was slightly increased
and this played a significant role in increasing KTP tablet hardness and decreasing percent
friability.
A concern with HME is the limitation of the drug loading due to drug-polymer
miscibility. In order to solve this issue, we investigated the effect of foam like structure produced
by pre P-CO2 on the drug loading and the dissolution profile of carbamazepine (CBZ) and low
molecular weight hydroxypropylcellulose (HPC) matrices using HME technique. The resulted
extrudates with P-CO2 injection exhibited higher surface area and porosity compared to the
extrudates processed without P-CO2. Moreover, the CBZ release profile of the 20-50% drug load
formulations processed with P-CO2 injection showed almost complete drug release within 2
hours. In contrast, the drug release profiles of 20%, 30%, 40% and 50% CBZ/ Klucel™ ELF
formulations processed without P-CO2 injection exhibited 90%, 86%, 80% and 73% CBZ drug
release, respectively. In conclusion, HME processing assisted with P-CO2 increased the drug
loading capability of CBZ in KlucelTM ELF polymeric matrix as well as optimized CBZ drugrelease profiles.

iii

Drug permeability and dissolution rate are considered as key to predict the drug
bioavailability. HME was used as an approach to improve solubility and permeability of the
psychoactive natural product piperine. Piperine 10–40% w/w formulated in Eudragit® EPO/
Kollidon® VA 64 or Soluplus® formulation was used in this study to investigate the efficiency of
various polymers to enhance the solubility and permeability of piperine via HME technique to
ultimately increase its systemic absorption of the compound. Scanning electron microscopy
(SEM) images showed absence of crystals in 10% w/w piperine/Soluplus® indicating that
piperine was dispersed in the Soluplus® polymer carrier in its amorphous form. However,
crystals were evident in all other formulations with different ratios. Solubility of 10% and 20%
piperine/Soluplus® was increased more than 160 and 45 folds in water, respectively.
Furthermore, permeability studies using non- everted rat intestinal sac model demonstrated the
enhancement in piperine absorption of the 10% w/w piperine/Soluplus® extrudates up to 158.9
μg/5mL compared to 1.4 μg/5mL in the case of pure piperine within 20 minutes.
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CHAPTER I
INTRODUCTION
Hot melt extrusion (HME) is a well-known processing technology which represents a novel
method to prepare solid dispersions. HME can simply be defined as a mixture of one or more
active pharmaceutical ingredients and at least one polymeric carrier forced through extrusion die
under controlled conditions to form a solid solution [1]. Being fast, simple, continuous and a
solvent free process, HME has received great attention in the pharmaceutical industry [2].
On the other hand most of the polymeric carriers have a high glass transition temperature (Tg) of
150 oC or more. Therefore, incorporation of a plasticizer is required in order to facilitate the
processing conditions as well as enhance the stability of the extrudates. The use of plasticizers
will lower the polymer viscosity due to the reduction in polymer Tg and therefore, increases the
thermal stability and minimizes the material thermal decomposition. There are many factors to
be considered to choose the suitable plasticizer such as the plasticizer efficiency, the plasticizerpolymer compatibility and the plasticizer stability. The resulting extrudates exhibit an elastic
smooth surface and low porosity. These extrudates properties may lower the formulation drug
release and also decrease the milling efficiency of those extrudates. The percentage of the
plasticizers in the formulation varies depending on the type of polymeric carrier as well as the
plasticizer efficacy. Incorporating plasticizers in pharmaceutical formulations will increase the
formulations final weight and result in patients complaints. Therefore, the use of a physical

1

blowing agent as a reversible plasticizer has gained a great interest in HME processing
technology.
Carbon dioxide (CO2) is considered as a great example for a physical blowing agent. It acts as a
reversible plasticizer and foaming agent [3]. CO2 is chemically inert and present in four different
state, with the change from state to state mainly depends on its temperature and the pressure.
Figure 1-1 shows the phase diagram of CO2 and its critical point of 31oC and 1073 Psi.

Figure 1-1: Phase diagram of carbon dioxide (CO2) [4]

2

There are many pharmaceutical applications for supercritical CO2 (SC-CO2) such as a
replacement to organic solvents in extraction, micro and nano particales formation, co-solvents,
co-precipitating agent, co-crystalizing agent, and in co-precipitation and solid dispersion
formation [5]. Additionally, there are also future prospects for the use of CO2 as a sterilizing
agent [6].
As hot melt extrudates have very low porosity structure which may slow down the penetration of
dissolution medium and alter the drug release, P-CO2 could be used as a blowing agent to
provide foamy extrudates with solid porous structure, therefore enhance the drug release.
Generally, production of foamed extrudates includes three main steps with in the drug polymer
mixtures; cell nucleation, cell growth and finally, the stabilization step [7]. At the first step, the
blowing gas implemented the melted mixture then the cell nucleation of the foam is initiated. At
the second step, expansion of the gas takes place, in which the growth of the foam structure
occurs. On the stabilization step, the foam formation is completed and the excess gas escapes at
the extrusion die.
Formation of foamy hot melt extrudates is described schematically in Figure 1-2. At the P-CO2
injection site, the sudden reduction in pressure and the increase in the temperature allows for the
diffusion of CO2 into the melted material. This condition helps to start the foam nucleation and
the foam structure growth [8].

3

Figure 1-2: Schematic diagram for the formation of foamy extrudates via hot melt extrusion
process.

.

4

Biopharmaceutics classification system divides the drug into four classes (figure 1-3) depending
on two important factors, solubility and permeability. These factors play a big role in the drug
absorption and bioavailability. Class I drug having no bioavailability issues as they have good
solubility and permeability and hence are easy to formulate for oral administration. While class
IV is considered the most difficult one as it represents the drug category which has poor
solubility and poor permeability. On the other hand, the biopharmaceutical properties of class II
(poor solubility/good permeability) and class III (good solubility and poor permeability) can be
modified to develop enhanced bioavailability oral formulations. These modifications can be
through enhancing the solubility via HME and other techniques or enhancing the permeability of
those drugs. Depending on the drug permeability mechanism of action, different methods can be
used to enhance the permeability. Permeability enhancers can be used in case of active
transportation mechanism while the HME can be used in case of passive transportation
mechanism.

Figure 1-3: Biopharmaceutics classification system by Shugarts et al. [9]
5

The specific objectives to the current research projects were to study the effect of P-CO2 on the
drug release and drug loading capacity using Ketoprofen (KTP) and Carbamazepine as drug
models. In addition, investigate the effect of different polymeric carriers using HME on the
solubility and permeability of a model drug piperine, is investigated.
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CHAPTER II
RESEARCH PROJECTS AND OBJECTIVES
2.1. Effect of Pressurized Carbon Dioxide on the Physico-Mechanical Properties of Hot
Melt Extruded Cellulose Polymers
2.1.1. Objectives:
The aims of the this research project were
1. To study the effect of Pressurized carbon dioxide (P-CO2) on the physico-mechanical

properties of cellulose polymers, Klucel™ LF, EF and ELF hydroxypropylcellulose (HPC)
resulting from hot melt extrusion techniques.
2.

To assess the plasticization effect of P-CO2 on the polymers tested (Klucel™ LF, EF and
ELF hydroxypropylcellulose (HPC).

2.2. Influence of Pressurized Carbon Dioxide on Ketoprofen-Incorporated Hot-Melt
Extruded Low Molecular Weight Hydroxypropylcellulose
2.2.1. Objective:
The goals of the current research project were to:
1. Investigate the effect of pressurized carbon dioxide (P-CO2) on the physicomechanical

properties of Ketoprofen (KTP) and hydroxypropylcellulose (HPC) matrices produced using
hot-melt extrusion (HME) techniques.
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2. Study the tablet characteristics of (KTP) and cellulose polymers prepared by Hot-Melt

Extrusion (HME) with and without injection of pressurized carbon dioxide (P-CO2).
2.3. Influence of Pressurized Carbon Dioxide on drug loading of High Melting Point
Carbamazepine and Low Molecular Weight Hydroxypropylcellulose Matrices Using Hot
Melt Extrusion
2.3.1. Objective
The main objective of this research was to investigate the effect of foam like structure produced
by pressurized carbon dioxide (P-CO2) on the drug loading and the dissolution profile of
carbamazepine (CBZ) and low molecular weight hydroxypropylcellulose (HPC) matrices using
hot-melt extrusion techniques.
2.4. Dissolution Enhancement of the Psychoactive Natural Product- Piperine Using Hot
Melt Extrusion Techniques
2.4.1. Objective
The aims of the current research project were to:
1. Investigate the efficiency of various polymers to enhance the solubility and dissolution rate

of piperine using hot melt extrusion techniques.
2. Increase the systemic absorption of piperine via enhancing its permeability.
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CHAPTER III
Effect of Pressurized Carbon Dioxide on the Physico-Mechanical Properties of Hot Melt
Extruded Cellulose Polymers
3.1. Introduction
Solubility is considered one of the most important factors to determine the oral bioavailability of
any active pharmaceutical ingredient (API) [10]. Over 40% of APIs are poorly water soluble and
result in low oral bioavailability[11]. Thus, enhancement of the solubility and oral bioavailability
of APIs has received much interest within the pharmaceutical research community. Various
techniques are used to overcome the poor water solubility of APIs such as salt formation,
solubilization by cosolvents, particle size reduction, pro-drug approaches, as well as the most
successful one to date, solid dispersion technique [10, 12] Solid dispersion is defined as “The
dispersion of one or more active ingredients in an inert carrier matrix at solid-state’’[13]. There
are many methods to prepare solid dispersions such as the fusion method, ball milling, solvent
evaporation, lyophilization, hot melt extrusion (HME) and supercritical ﬂuid methods [14-16]
HME has received increasing attention in the pharmaceutical industry over the last few decades
as a beneficial technique to produce solid dispersions[17]. There are many advantages of using
HME over the conventional pharmaceutical processing methods, such as it is a relatively fast,
continuous manufacturing process [18, 19] and it can convert an active pharmaceutical ingredient
(API) into its amorphous state [20]. Moreover, another important advantage of HME is that no
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solvent is required, so it is considered a “green method” to enhance the solubility and oral
bioavailability of poorly water soluble drugs [21, 22]. However, a concern of HME is drug and
polymer degradation due to potential high processing temperature. Thus, in case of thermo-labile
drugs, processing aids or plasticizers might be added to reduce the viscosity and lower the
minimum processing temperature, thus decreasing both drug and polymer degradation [23].
Choice of plasticizers as processing aids in HME depends on the compatibility between the drug
and other excipients in the formulation. Use of plasticizers may affect the physico-mechanical
properties and drug release profiles of the hot melt extrudates. Plasticizers often increase the
elasticity and flexibility of the extrudates [23]. Some plasticizers adversely affect the storage
stability of pharmaceutical formulations resulting in changes within their release profiles [24].
It has been reported that P-CO2 can act as a reversible plasticizer and foaming agent [25]. CO2 is
non-toxic, nonflammable and chemically inert in nature [26, 27]. These properties could increase
the interest in the combination of P-CO2 and HME [28]. Previous investigations have shown that
P-CO2 when injected during HME processing acts as a plasticizer for some pharmaceutically
utilized polymers, such as Eudragit® E100, polyvinylpyrrolidone-co-vinylacetate 64 (PVP-VA
64) and ethylcellulose 20 centipoise (EC 20 cps), (allowing for a decrease in their T g) [29] and
thus, reduction in the extrusion processing temperatures [3, 30-33]. Within the HME process, PCO2 changes the microscopic morphology of the extrudates to foam-like structures due to its
expansion characteristics at the extrusion die [25, 34]. This morphological change could result in
increasing the surface area and porosity , thereby, enhancing the milling efficiency of hot melt
extrudates [30, 35] . In the recent past, several studies have evaluated the effect of supercritical
CO2 on HME processing. However, limited studies have been conducted to study the effect of
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the pressurized (subcritical) state of CO2. P- CO2 entails more advantages than supercritical CO2
such as being more economical since no pump is required.
Hydroxypropyl cellulose (HPC) (Figure 3-1) is non-ionic water soluble cellulose ether. It has
many pharmaceutical applications such as an emulsion stabilizer, binder, film-former, thickener
and drug carrier [36]. Typically, HPC extrudates may be difficult to mill due to its high elasticity
and hygroscopicity [37]. An objective of this study is to resolve this potential issue.

Figure 3-1: Chemical structure of Hydroxypropylcellulose (HPC).
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3.2. Materials
Klucel™ LF, EF and ELF hydroxypropylcellulose (HPC) and polyplasdone XL TM were obtained
as gift samples from Ashland Inc (Wilmington, DW 19808 USA). Propylene glycol and
Magnesium Stearate were purchased from Spectrum Chemicals (14422 S. San Pedro Street
Gardena, CA 90248 USA). CO2 was supplied in gas cylinders (pure clean) from Airgas (902
Rockefeller St, Tupelo, MS 38801 USA), Avicel®102 was received as a gift sample from FMC
biopolymers (1735 Market Street, Philadelphia PA 19103 USA). Aerosil® was obtained as a gift
sample from Evonik degussa Corporation (379 Interpace Parkway, Parsippany, NJ 07054 USA).
All other chemicals and reagents used in the present study were of analytical grade and obtained
from Fisher scientific (Fair Lawn, NJ 07410 USA).
3.3. Methodology
3.3.1. Thermogravimetric Analysis (TGA)
TGA studies were performed for Klucel™ LF, EF and ELF hydroxypropylcellulose (HPC) to
determine their stability at the extrusion temperatures using a Perkin Elmer Pyris 1 TGA
equipped with Pyris manager software (PerkinElmer Life and Analytical Sciences, 710
Bridgeport Ave., Connecticut, USA).
3.3.2. Hot Melt Extrusion (HME)
The HME processes were performed using a twin-screw extruder (16 mm Prism Euro Lab,
ThermoFisher Scientific). The extruder is divided into 10-barrel segments adjacent to the
gravimetric feeder. Thermo Fisher Scientific standard screw configuration was used for this
study, which consists of four conveying segments and three mixing zones and all of the injections
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were made through the injection port at the conveying zones of the screw configuration (Figure
3-2).

Conveying elements

Feed Port

DIE

Zone 10

Zone 9

Mixing elements

Feed Port

Zone 8

Zone 7

Zone 6

Feed Port

Zone 5

Zone 4

Feed Port

Zone 3

Zone 2

Figure 3-2: Types of screw elements and the screw configuration.
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Feeding
Zone

All of the formulations as mentioned in (Table 3-1) were extruded at maximum torque possible.
The screw speed was 100 rpm at a temperature range from 90-140°C and, at a feed rate of ~
0.7Kg/hr. The propylene glycol was injected in a barrel segment 4 using Watson-Marlow 520S
IP31 Pump.

Table 3-1: Formulation composition of HME

Formulation

KlucelTM
ELF
(%)

KlucelTM
EF
(%)

KlucelTM
LF
(%)

Propyleneglycol (PG)
(%)

CO2 Injection
Zone

K1

100

-

-

-

-

K2

-

100

-

-

-

K3

-

-

100

-

-

K4

100

-

-

-

Zone 4

K5

-

100

-

-

Zone 4

K6

-

-

100

-

Zone 4

K7

95

-

-

5

-

K8

-

95

-

5

-

K9

-

-

95

5

-
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CO2 was pressurized and injected into the extruder using a high-pressure regulator connected to
flexible stainless steel hose with armor casing. The other end of the hose was connected to the
four-way connection, fitted with a pressure gauge, bleed valve, check valve (ball type for
unidirectional flow of gas), with the later being connected to the injection port seating on the
extruder in barrel segment 4 or 6 (Figure 3-3). Metering of CO2 was regulated using the regulator
knob.

Figure 3-3: Schematic diagram for P-CO2 injection in hot melt extrusion processing.
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3.3.3. Light Microscopy
To evaluate the microscopic morphology of the extrudates with and without P-CO2 injection and,
with the addition of 5% PG, light microscope with camera was used. Thin transverse section (TS)
of extrudates were placed on glass slides and observed under the microscope. Photographs of TS
samples were taken with zoom power 3x.
3.3.4. Milling
The hot melt extrudates were milled and passed through ASTM mesh sieve #35 using a
comminuting mill (Fitzpatrick, Model L1A).
3.3.5. Tabletting
The milled extrudates were used to prepare the tablet blends using microcystalline cellulose
(Avicel®102) as diluent, colloidal silicon dioxide (Arosil®) as flowability enhancer,
polyplasedone XL

TM

as a disintegrant and magnesium stearate as a lubricant (Table 1-2). The

tablet blends were compressed with the same compression force (1.5-1.6 kN) on a manual tablet
press using 8 mm biconcave punch to a final tablet weighing 175mg. The tablet properties such
as thickness, hardness and tablets percent friability were performed. A digital caliper was used to
obtain the tablet thickness. Optimal control tablet hardness tester was used for the tablet hardness
determination. The percent friability was calculated for each batch using a Vanderkamper
friability tester by applying the following equation.

𝐹=

𝑊1−𝑊2
𝑊1

× 100

(Equation 3-1)

Where F is percent friability, and W1 and W2 are the initial and final tablet weights,
respectively.

16

Table 3-2: Placebo tablet composition for non-API extrudates with and without P-CO2
injection and physical mixture of non-extruded polymers
Excipients

% (w/w)

Weight (mg/tablet)

KlucelTM (ELF/EF/LF)

28.57

50.00

Avicel® 102

68.00

119.00

Aerosil®

0.57

1.00

PolyplasdoneTM XL

2.29

4.00

Magnesium stearate

0.57

1.00
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3.4. Results and Discussions
3.4.1. Thermal Analysis
Thermogravimetric Analysis (TGA) is a technique in which the material sample weight is
monitored as a function of temperature. TGA is an essential laboratory tool used to determine the
material decomposition temperature and the moisture content. The TGA data demonstrated that
Klucel™ ELF, EF and LF depredation temperatures were about 300 oC in which the polymers
start losing weight with increasing the temperature. From the TGA thermogram we can conclude
that all the polymers used in this study were stable under the employed extrusion processing
temperature (120 oC- 140 oC) which is way lower than their decomposing temperatures (Figure

Weight % (%)

3-4).

Temperature (oC)

Figure 3-4: TGA thermogram of that Klucel™ ELF, EF and LF.
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3.4.2. Hot Melt Extrusion
During extrusion with P-CO2 injection, metering of CO2 was controlled using the regulator until
the reading on the pressure gauge located at the 4-way connector was maintained between 75-150
psi. CO2 was provided in a liquid form from a CO2 gas cylinder (pure clean). The back pressure
from the injection port maintained the CO2 in a liquid state that further dropped the temperature
at the injection port as low as 2°C. The injection zone should be completely filled with the
physical mixture for the formation of the melt seals to prevent any leakage of gas from the
extruder and allow good mixing between the materials and CO2. As described by Verreck et al.,
2007d, diffusion and dissolution of the injected P-CO2 in the polymers manifested as extremely
foamy extrudates with the increment of die swelling accompanied by CO2 expansion at the
terminal end of the die (Figure 3-5).
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(Foamy extrudates)

Without P-CO2
injection

With P-CO2
injection

With P-CO2
injection

Without P-CO2
injection

Figure 3-5: HME extrudates processed with and without P-CO2 injection.

As investigated by Repka et al., HPC extrudates were more dense, flexible and hygroscopic [37].
While, upon injection of PG in zone 4, the extrudates were sticky and elastic. Injection of PG as a
plasticizer reduced the extrusion processing temperature by about 30oC. However, the P-CO2 can
also act as a plasticizer which has been previously mentioned by Lyons et al. [33]. In
formulations of k4, k5 and k6 when P-CO2 was injected in zone 4, the processing temperature
decreased by about 20°C as compared to the processing temperature without injecting P-CO2
(Table 3-3).
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Table 3-3: Processing parameters for hot melt extrusion process of K1- K9
Formulation

Extrusion Temp. (oC)

Screw Speed (rpm)

Torque (Nm)

K1

140

100

21-22

K2

140

100

22

K3

140

100

20-22

100

18-18.5

100

18

100

17-19

K4

K5

K6

Zone 2-4 (140 oC)
Rest of the zones (120 oC)
Zone 2-4 (140 oC)
Rest of the zones (120 oC)
Zone 2-4 (140 oC)
Rest of the zones (120oC)

K7

90

100

12-16

K8

90

100

12-17

K9

90

100

14-18
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These findings confirmed that CO2 acts as a reversible plasticizer and escapes from the
formulation at the end of HME processing and no more weight will be added to the formulation
as shown by Verreck et al. [31]. Furthermore, CO2 is chemically inert, so the compatibility issue
of other plasticizers with the polymers used in the study was avoided. The microscopical images
of the extrudates processed with P-CO2 injection demonstrated higher surface area and porosity
as compared to the extrudates processed without P-CO2 injection and, the one with PG injection
(Figure 3-6).
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b

c

d

e

f

g

h

i

a
a

Figuer 3-6: Microscopy photographs of KlucelTM (ELF, EF, and LF) extrudates with
and without P-CO2 injection, or with PG injection (Magnification 3X). (a) ELF
without P-CO2, (b) ELF with P-CO2, (c) ELF with PG injection, (d) EF without PCO2, (e) EF with P-CO2, (f) EF with PG injection, (g) LF without P-CO2, (h) LF with
P-CO2, (i) LF with PG injection.
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HPC extrudates typically are very difficult to be milled and a freezing process is required before
the milling procedure [38]. Because of the high flexibility and hygroscopicity of the extrudates
with PG injection, milling failing occurs due to the shutdown of the Fitzmill as a result of
generation of maximum torque (Figure 3-7).

Figure 3-7: Failed milling of KlucelTM (ELF, EF, and LF) extrudates with PG
injection.

The phenomenon of milling failing on these extrudates with PG injection could not be improved
even when the freezing process is used before the milling. Milling process is an essential step in
the pharmaceutical industries and failing of this step will prevent any further processing into
suitable dosage forms. A significant enhancement of the milling efficiency of extrudates with PCO2 injection was observed. The milling efficiency was determined by the torque value of the
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Fitzmill. As mentioned by Verreck et al.[30] these processing properties of the materials would
provide numerous benefits during manufacturing of various solid dosage forms such as tablets
and capsules.
Jeong et al. has shown that there is a lowering in bulk density of extrudates in the presence of PCO2 injection [39]. Our results showed that foamed milled extrudates exhibited lower bulk
density and tap density as compared to the extrudates without P-CO2 injection, due to an increase
in porosity and surface area of the extrudates (Table 3-4).

Table 3-4: Bulk and tap density of milled extrudates with and without P-CO2 injection
(g/mL) ±SD (n=3)
Without P-CO2 injection

With P-CO2 injection

Sample name
Bulk density

Tap density

Bulk density

Tap density

KlucelTM ELF

0.265± 0.009

0.366± 0.011

0.154± 0.003

0.241± 0.002

KlucelTM EF

0.294± 0.007

0.441± 0.008

0.131± 0.002

0.213± 0.005

KlucelTM LF

0.304± 0.013

0.435± 0.004

0.191± 0.004

0.227± 0.007
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3.4.3. Tablets evaluation
The bulk density and tap density of the tablet blends prepared with extrudates processed with PCO2 injection was lower as compared to the other blends without P-CO2 injection and
unprocessed physical mixtures, as a result of the foam extrudates (Table 3-5).

Table 3-5: Bulk and Tap density of placebo tablet blends (g/mL)
Physical mixture

Without P-CO2

With P-CO2 injection

injection
Sample name

Bulk

Tap

Bulk

Tap

Bulk

Tap

Density

Density

Density

Density

Density

Density

KlucelTMELF

0.393

0.492

0.366

0.473

0.303

0.419

KlucelTM EF

0.395

0.510

0.385

0.485

0.303

0.413

KlucelTM LF

0.407

0.516

0.393

0.492

0.354

0.462
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The evaluation of all Klucel™ ELF, EF and LF placebo tablets showed that the tablet weight
variations of all the formulations were acceptable with very low standard deviations (SD < 1.0).
In case of the tablets prepared with foamed extrudates, tablet hardness was enhanced by 22%33% compared to those prepared by extrudates without P-CO2 injection and unprocessed
physical mixtures (Figure 3-8). Tablet friability was evaluated for all of the formulations and the
results showed lowering in the % friability of tablets prepared with foamy extrudates (less than
0.3%) as compared to the other tablet formulations (0.6%-1.7%) (Figure 3-9). These results
indicated good binding properties and compressibility of foamy extrudates.

Placebo Tablets
9

Tablet Hardness (kp)

8
7
6
5

Physical mixture

4

Without CO2
With CO2

3
2
1
0

ELF

EF

LF

Figure 3-8: Hardness in (kp) of Klucel TM ELF/EF/LF placebo tablets.
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Placebo Tablets
2

% Friability

1.5

1

0.5

0

ELF
Physical mixture

EF
Without CO2

LF
With CO2

Figure 3-9: % Friability of Klucel TM ELF/EF/LF placebo tablets.
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3.5. Conclusion
P-CO2 acted as a temporary plasticizer for KlucelTM ELF, EF, and LF when injected in zone 4
during HME processing, allowing reduction in extrusion temperatures. Whereas, when the P-CO2
was injected in zone 6 the reduction in extrusion temperature was not feasible. Thus, the zone in
which P-CO2 is injected plays a significant role in melt extrusion processing. The microscopic
morphology of the extrudates with P-CO2 injection was changed to a foam-like structure, which
increases their surface area and porosity. Moreover, the milling efficiency of all extrudates
processed with P-CO2 was enhanced, which may be beneficial for optimizing the manufacturing
of solid dosage forms. A combination of P-CO2 and HME improved the tablet properties (higher
hardness & lower friability) indicating good binding properties and compressibility of the blends.
Acknowledgement
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CHAPTER IV
Influence of Pressurized Carbon Dioxide on Ketoprofen-Incorporated Hot-Melt Extruded
Low Molecular Weight Hydroxypropylcellulose
4.1. Introduction:
HME is commonly used in the pharmaceutical industry for solubility enhancement applications.
Carbon dioxide is non-toxic, non-flammable, and chemically inert [26, 27]. It was observed in
earlier study that hot-melt extrusion processing assisted with P-CO2 increased porosity and the
surface area of the extrudates and changed the macroscopic morphology to a foam-like structure
and furthermore enhanced the milling efficiency. Additionally, the drug dissolution rates
increased significantly up on foaming extrudates structures. In this current research study, the
main objective was to evaluate the effect of P-CO2 on ketoprofen (KTP) and HPC polymers
using HME techniques. The model drug KTP (Figure 4-1) is a non-steroidal anti-inflammatory
agent[40] and, it is crystalline in nature with poor water solubility [41]. It is conventionally
formulated as an oral dosage form [42]. It is thermally stable with a melting point of
approximately 95oC and “burns out” over a temperature range of 235-400oC [43]. Indeed the
literature has recently reported that hot melt extudates of KTP and HPC has demonstrated poor
milling efficiency [38]. In order to solve these underlining issues, in the present study we
investigated the effect of P-CO2 on the physico-mechanical properties as well as the release
profiles of KTP and HPC extrudates produced using HME techniques.
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Figure 4-1: Chemical structure of Ketoprofen (KTP)

4.2. Material
Klucel™ LF, EF and ELF hydroxypropylcellulose (HPC) and polyplasdone XL TM were obtained
as gift samples from Ashland Inc. (Wilmington, DW 19808 USA). Ketoprofen was purchased
from Parchem-Fine & specialty chemicals (415 Huguenot St, New Rochelle, NY 10801 USA).
CO2 was supplied in gas cylinders (pure clean) from Airgas (902 Rockefeller St, Tupelo, MS
38801 USA), Avicel®102 was received as a gift samples from FMC biopolymers (1735 Market
Street, Philadelphia PA 19103 USA). Flow lac® 90 was received as a gift samples from Meggle
USA Inc. (50 Main street, White Plains, NY 10606 USA). Syloid® was received from W. R.
Grace & Co.- Conn (7500 Grace Drive, Columbia, MD 21044 USA). Magnesium Stearate was
purchased from Spectrum Chemicals (14422 S. San Pedro Street Gardena, CA 90248 USA). All
other chemicals and reagents used in the present study were of analytical grade and obtained
from Fisher scientific (Fair Lawn, NJ 07410 USA).
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4.3. Method
4.3.1. Thermal Analysis
4.3.1.1. Thermogravimetric Analysis (TGA)
TGA studies were performed for KTP and polymers used in this study to determine their stability
at the extrusion temperatures using a Perkin Elmer Pyris 1 TGA equipped with Pyris manager
software (PerkinElmer Life and Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA.
4.3.1.2. Differential Scanning Calorimetry (DSC)
DSC was obtained using Perkin Elmer Pyris 1 DSC equipped with Pyris manager software
(PerkinElmer Life and Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA).
Approximately 2-4 mg of KTP, physical mixtures or extrudates were heated from 30°C to 200
°C at heating rate of 10°C/min.
4.3.2. Physical mixture
KTP and Klucel

TM

LF, EF and ELF hydroxypropylcellulose (HPC) polymers were sieved using

ASTM #35 mesh. Physical mixture of 15% w/w KTP with each polymer were mixed using a VShell blender for 10 minutes. Tree samples from each physical mixture were analyzed for blend
drug content and uniformity.
4.3.3. Hot Melt Extrusion
The physical mixture blends (Table 4-1) were extruded with or without P-CO2 injection using a
twin-screw extruder (16 mm Prism EuroLab, ThermoFisher Scientific) (Figure 4-2) at screw
speeds of 100 rpm (temp range: 90–140°C) (Table 4-2) P-CO2 was injected into the extruder as

32

described previously in chapter I using a high-pressure regulator connected with flexible
stainless steel armor-cased hosing. The other end of the hose was connected to the injection port
seating on segment 6 of the extruder barrel (Figure 4-3).

Table 4-1: Formulation composition of HME

Formulation KTP (%)

KlucelTM

KlucelTM EF

KlucelTM LF

CO2 injection

ELF (%)

(%)

(%)

zone

K10

15

85

-

-

-

K11

15

-

85

-

-

K12

15

-

-

85

-

K13

15

85

-

-

Zone 6

K14

15

-

85

-

Zone 6

K15

15

-

-

85

Zone 6
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Table 4-2: Processing parameters for hot melt extrusion process of K10-K15
Formulation

Extrusion Temp. (oC)

Screw Speed (rpm)

Torque (Nm)

K10

110

75

9-14

K11

110

75

9-12

K12

110

75

11-13

K13

100

75

8-9

K14

100

75

9-10

K15

100

75

9-12
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Figure 4-2: 16 mm Prism EuroLab, ThermoFisher Scientific.

Figure 4-3: P-CO2 injection port.
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4.3.4. Microscopical images
Microscopy photographs were performed for thin transverse section (TS) of all extrudates using
light microscope with camera (Nikon SMZ-U). Photographs of TS samples were taken with
zoom power 3x.
4.3.5. Milling
All the extrudates were milled and sieved through ASTM #35 mesh using a comminuting mill
(Fitzpatrick, Model L1A).
4.3.6. High-Performance Liquid Chromatography (HPLC)
All samples were analyzed using a Waters HPLC equipped with Empower software to analyze
the data. HPLC consisted of a Water 600 binary pump, Waters 2489 UV/detector, and Waters
717 plus autosampler (Waters Technologies Corporation, 34 Maple St., Milford, MA 0157). The
column used was phenomenex luna C18 (5µ, 250 mm × 4.6 mm). The mobile phase constituted
of acetonitrile/20 mMol phosphate buffer, 55:45 (%v/v) at pH 4 [38, 44] at a flow rate of 1
mL/min and injection volume of 20 μl. The UV detector wavelength for KTP detection was set at
256 nm.
4.3.7. In Vitro Drug Release
Extrudates equivalent to 25 mg KTP were filled in HPMC capsules and in vitro drug release
profiles were performed using a USP type II dissolution apparatus. The dissolution media was
1000 mL 0.05 M phosphate buffer pH 7.4 and, was maintained at 37 oC. A sample volume of 2
mL were taken at time points 10, 20, 30, 45, 60 min. [45], filtered and analyzed using HPLC and
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2 mL of fresh dissolution media were added back to the dissolution vessel at each time point.
The release profiles of 25 mg KTP tablets were obtained in the same conditions.
4.3.8. Tabletting
4.3.8.1. Tablet preparation
The milled extrudates were used to prepare the tablet blends using microcystalline cellulose
(Avicel®102) or lactose (flow lac® 90) as diluent, silicon dioxide (Syloid®) as flowability
enhancer, polyplasedone XL TM as a disintegrant and magnesium stearate as a lubricant (Table 43). The 25 mg strength tablets were compressed with the same compression force (1.5-1.6 kN)
on a manual tablet press using 10 mm biconcave punch to a final tablet weight of 350 mg.

Table 4-3: KTP tablet composition of extrudates with and without P-CO2 injection
Excipients

% (w/w)

Weight (mg/tablet)

KTP

7.14

25.00

KlucelTM (ELF/EF/LF)

40.46

141.66

Avicel® 102

24.60

86.10

Flowlac 90

12.30

43.05

Syloid®

10.00

35.00

PolyplasdoneTM XL

5.00

17.5

Magnesium stearate

0.50

1.75

37

4.3.8.2. Tablet Evaluation
Tablets were evaluated for thickness, hardness, friability, and disintegration time as well as
release profiles.
4.3.9. Moisture Analysis
To evaluate the moisture content of the extrudates , OHOUS MB45 moisture analyzer was used.
6-7 gm. of the extrudates placed in the sample pan and inserted in the sample chamber and then
heated to 110 oC for 15 minutes. Samples weight loss of drying was recorded as well as the % of
the moisture.
4.3.10. Stability Study
All KTP/Klucel TM ELF, EF and LF extrudates with and without P-CO2 injection were sealed in
glass bottles and stored at 25oC/60% RH for three months. Recrystallization assessments were
determined by DSC.
4.4. Results and discussion
4.4.1. Thermal Analysis
TGA data demonstrated that all formulations utilized in this study were stable under the
employed processing temperature (Figure 4-4).
Differential Scanning Calorimetry, or DSC, is a thermal analysis technique evaluates how a
material’s heat capacity (Cp) is changed by temperature. The information generate by DSC is
used to understand amorphous and crystalline behavior of the polymer and drug in the
pharmaceutical industries. The DSC data showed that ketoprofen melting peaks at 90oC
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disappeared for all of the milled extrudates with and without P-CO2 injection, which indicated
the conversion of the crystalline form into the amorphous form. All milled extrudates remained
in an amorphous form at the end of the last time point after 3 months of storage at 25 oC/60% RH
(Figure 4-5).

Figure 4-4: TGA thermogram of that Ketoprofen and Klucel™ ELF, EF and LF.
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Figure 4-5: DSC thermogram of Ketoprofen, physical mixture and extrudates with and
without P-CO2 injection at 0, 1, 2, 3 months.
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4.4.2. Hot Melt Extrusion
Hot melt extrusion processes were performed using 16 mm Prism Euro Lab, Thermo Fisher
Scientific) with Thermo Fisher Scientific standard screw configuration. The injections were made
through the injection port at the conveying zone of the screw configuration. The resulted
extrudates processed without P-CO2 injection were dense, opaque, elastic and sticky extrudates
with all polymeric matrices. While other extrudates which processed with P-CO2 were foamy and
porous extrudates (Figure 4-6).

Foamy extrudates
with P-CO2 injection

Regular extrudates
without P-CO2 injection

Figure 4-6: KTP/ Klucel

TM

extrudates with and without P-CO2 injection.
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The microscopical images of the TS sections of different extrudates showed that the porosity of
the extrudates processed with P-CO2 was increased (Figure 4-7). This change in the extrudates
morphological properties was due to the expansion of the carbon dioxide at the extrusion die.

Without CO2

With CO2

a

b

c

Figure 4-7: Microscopy photographs of TS sections of a) 15% KTP& Klucel
TM

b) 15% KTP& Klucel EF, and c) 15% KTP& Klucel
without P-CO2 injections (Magnification 3X).
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TM

TM

ELF

EF extrudates with and

As observed previously, the milling efficiency of the extrudates processed with P-CO2 was
enhanced compared with extrudates processed without P-CO2 (Figure 4-8). The foamed milled
extrudates exhibited lower bulk density and tap density as compared to the extrudates processed
without P-CO2 injection, due to an increase in porosity and surface area of the extrudates (Table
4-4).

Dry ice + Milling

Without P-CO2 injection

Milled extrudates

Milling
With P-CO2 injection

Figure 4-8: Milling processing and milled extrudates.
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Table 4-4: Bulk and tap density of milled extrudates with and without P-CO2 injection
(g/mL)

Without P-CO2 injection

With P-CO2 injection

Sample name

KTP/ KlucelTM
ELF
KTP/ KlucelTM
EF
KTP/ KlucelTM
LF

Bulk density

Tap density

Bulk density

Tap density

0.382± 0.012

0.434± 0.008

0.175± 0.001

0.270± 0.003

0.286± 0.009

0.373± 0.007

0.150± 0.001

0.235± 0.005

0.325± 0.013

0.415±0.011

0.145± 0.002

0.240± 0.006

4.4.3. Drug Content
HPLC analysis confirmed that the drug content uniformity of KTP in all formulations were
acceptable and within the range of 98-105%. These results indicated good homogeneity of all
formulations.
4.4.4. In-vitro Drug Release
The in vitro drug release concedes as an important aspect in drug development that reflect drug
in vivo performance [46]. The in vitro dissolution profiles were performed to evaluate the KTP/
Klucel™ ELF, EF and LF release behavior of milled extrudates with or without P-CO2 injection
as well as unprocessed physical mixtures. Plots of time vs. % drug release, which is the average
of three replicates, were used as dissolution profiles for different formulations (Figures 4-9, 4-10,
and 4-11). These profiles demonstrated a significant improvement of KTP release in the presence
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of P-CO2 injection as compared to the other formulations. The release enhancement was
observed as a direct result of the foam-like structure and high surface area of those extrudates
with P-CO2 injection[47-50].

KTP/ELF
100

% Drug release

80
60
PM
without CO2

40

With CO2
20
0
0

10

20

30
Time in (min.)

40

50

60

Figure 4-9: Dissolution profiles of KTP/KlucelTM ELF extrudates with and without PCO2 injection and physical mixture (pH 7.4 phosphate buffers, USP App II, 50
rpm/37oC).
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KTP/ EF
100

% Drug release

80
60
PM
40

without CO2
With CO2
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40

50

60

Figure 4-10: Dissolution profiles of KTP/KlucelTM EF extrudates with and without PCO2 injection and physical mixture (pH 7.4 phosphate buffers, USP App II, 50
rpm/37oC).

KTP/LF
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% Drug release
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20
0
0

10

20

30
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Figure 4-11: Dissolution profiles of KTP/KlucelTM LF extrudates with and without PCO2 injection and physical mixture (pH 7.4 phosphate buffers, USP App II, 50
rpm/37oC).
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4.4.5. Tablet Evaluation
The tablet blends prepared with extrudates processed with P-CO2 injection showed lower bulk
and tap density compared to other tablet blends due to formation of foam like structure as well as
increase porosity and surface area of these extrudates (Table 4-5).

Table 4-5: Bulk and Tap density of KTP tablet blends (g/mL)

Physical mixture

Without P-CO2

With P-CO2

injection

injection

Sample Name

KTP/ KlucelTM
ELF
KTP/ KlucelTM
EF
KTP/ KlucelTM
LF

Bulk

Tap

Bulk

Tap

Bulk

Tap

Density

Density

Density

Density

Density

Density

0.40

0.61

0.46

0.66

0.35

0.49

0.39

0.57

0.44

0.59

0.33

0.47

0.39

0.57

0.44

0.59

0.33

0.47
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Tablets were successfully prepared (Figure 4-12) and showed that the drug content of all
formulations ranged from 96-110% indicating good drug uniformity of all formulations.
Furthermore, tablet weight variations of all the formulations were very low with standard
deviations (SD < 1.0).

Figure 4-12: Ketoprofen tablets.

Tablets processed using P-CO2 assisted extrudates exhibited higher hardness (Figure 4-13) and
lower % friability (Figure 4-14) due to good binding properties and compressibility of the
extrudates, as compared to those not processed with P-CO2. To understand this phenomenon,
moisture content of the extrudates was performed. Table 4-6 showed the moisture content of the
extruades with and without P-CO2 injection. The results clearly demonstrated that extrudateds
processed with P-CO2 having more moisture than extrudateds processed without P-CO2. This
observation explained the increases of the tablet hardness in case of using blends of extrudateds
processed with P-CO2.
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KTP/ Klucel TM ELF/EF/LF Tablets
12

Tablet Hardness (kp)

10

8

6

4

2

0

KTP/ELF
Physical mixture

KTP/EF

KTP/LF

Without CO2

Figure 4-13: Hardness in (kp) of KTP/Klucel
without P-CO2 injection and physical mixture.
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With CO2
TM

ELF/EF/LF tablets, with and

KTP/KlucelTM ELF/EF/ELF Tablets
2

% Friability

1.5

1

0.5

0

KTP/ELF
Physical mixture

KTP/EF
Without CO2

Figure 4-14: % Friability of KTP/Klucel
P-CO2 injection and physical mixture.

TM

50

KTP/LF
With CO2

ELF/EF/LF tablets, with and without

Table 4-6: Moisture content of KTP/ KlucelTM ELF, EF, and LF
LOD%
Sample Name
Without P-CO2

With P-CO2

KTP/ KlucelTM ELF

0.53

0.88

KTP/ KlucelTM EF

0.69

0.91

KTP/ KlucelTM LF

0.56

1.54

The tablets were also subjected to in vitro dissolution studies of KTP/ KlucelTM EF tablets with
and without P-CO2 injection. No significant differences were observed in the drug release
profiles of tablets with and without P-CO2 extrudates (Figure 4-15). These results indicate that
the dissolution improvement of extrudates processed with P-CO2 was due to the high surface
area and porosity, as compared to the extrudates without P-CO2 injection. Whereas, when these
extrudates were compressed into tablets, the compression force reduced the surface area of the
foamy extrudates which eliminates the dissolution improvements utilizing P-CO2 injections.
Therefore, there was no effect of P-CO2 injection on the tablet release profile.
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100

% Drug release
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Figure 4-15: Dissolution profiles of KTP/KlucelTM EF tablets with and without P-CO2
injection (pH 7.4 phosphate buffers, USP App II, 50 rpm and 37oC).
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4.5. Conclusion
It has been observed that Hot-melt extrusion processing assisted with P-CO2 increased porosity
of the KTP/ KlucelTM ELF, EF and LF extrudates and changed the macroscopic morphology to a
foam-like structure due to expansion of the carbon dioxide at the extrusion die. These properties
allowed enhancement of the milling efficiency of the extudates assisted with P-CO2.
Furthermore, the extrudates processed with P-CO2 injection demonstrated an enhancement of
KTP release as compared to the physical mixtures and the extrudates processed without P-CO2
injection, due to the increase in the surface area and porosity. However, there was no significant
difference in the drug release profiles of tablets prepared with or without CO2 extrudates after the
compression process, which indicates that P-CO2 injection does not alter the drug release profiles
of tablets. Alternatively, it instead improves the processing properties of the tablets. P-CO2
utilized in HME processing may exhibit similar benefits of supercritical CO2 while avoiding
some of the disadvantages experienced when utilized at the supercritical fluid level.
Acknowledgement
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CHAPTER V
Influence of Pressurized Carbon Dioxide on drug loading of High Melting Point
Carbamazepine and Low Molecular Weight Hydroxypropylcellulose Matrices Using Hot
Melt Extrusion
5.1. Introduction
Carbamazepine (CBZ) (Figure 5-1) is an anticonvulsant drug used in the treatment of epilepsy,
bipolar disorder and specific analgesic for trigeminal neuralgia [51, 52]. Biopharmaceutics
Classification System categorized CBZ as class II with poor water solubility and good
permeability [53]. It has prolonged absorption rate due to its lower dissolution rate [54].
However, CBZ crystalizes under at least four polymorphic crystal forms which include; Triclinic
(Form I), Trigonal (Form II), P-Monoclinic (Form III), C-Monoclinic (Form IV). Variations in
dissolution rate and absorption rate of CBZ have been reported due to the presence of the drug in
different crystalline forms [55]. To overcome this issue, CBZ solid dispersion formulations were
prepared by different methods to produce uniform and stable CBZ solid dispersion and to
minimize the absorption variability. Zerrouk et al used fusion and crystallization to prepare the
solid dispersion of CBZ with PEG 6000 and observed the ability of PEG 6000 to enhance the
CBZ solubility [56]. Soluplus and polyvinylpyrrolidone (PVP/ VA 64) were used as polymeric
carriers to prepare CBZ solid dispersion via HME process [53, 57]. However, a concern of HME
is the limitation of the drug loading due to drug-polymer miscibility. In a previous study, we
investigated the effect of P-CO2 on the physico-mechanical properties as well as the drug release
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profile using HME process. Successfully, foamed extrudates were prepared with high surface
area and enhanced drug release profiles [58]. Elizondo et al observed that P-CO2 can be used to
prepare highly loaded antibiotic nanostructured PVM/MA matrices [59]. Considering these
observations, it would be interesting to investigate the effect of P-CO2 on the drug loading and
the dissolution profiles of CBZ processed by HME.

Figure 5-1: Chemical structure of Carbamazepine (CBZ).

5.2. Material
Klucel™ ELF hydroxypropylcellulose (HPC) was received as gift samples from Ashland Inc
(Wilmington, DW 19808 USA). CBZ was purchased from AFINE Chemicals Limited (Sandun
Town, Hangzhou 310030 China). CO2 was supplied in gas cylinders (pure clean) from Airgas
(902 Rockefeller St, Tupelo, MS 38801 USA). All other chemicals and reagents used in the
present study were of analytical grade and obtained from Fisher scientific (Fair Lawn, NJ 07410
USA).
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5.3. Method
5.3.1. Thermal Analysis
5.3.1.1. Thermogravimetric Analysis (TGA)
TGA studies were performed for CBZ and Klucel

TM

ELF to determine their stability at the

extrusion temperatures using a Perkin Elmer Pyris 1 TGA equipped with Pyris manager software
(PerkinElmer Life and Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA). 7-10 mg.
of the sample was weighed and heated from 30°C to 400 °C at heating rate of 20°C/min under
nitrogen purging.
5.3.1.2. Differential Scanning Calorimetry (DSC)
DSC was performed to evaluate the drug polymer miscibility at different drug loading as well as
the physical state of the all extrudates using Perkin Elmer Pyris 1 DSC equipped with Pyris
manager software (PerkinElmer Life and Analytical Sciences, 710 Bridgeport Ave., Connecticut,
USA). Approximately 2-4 mg of CBZ, physical mixtures or extrudates were heated from 30°C to
230°C at heating rate of 10°C/min. DSC data are also used to evaluate the % crystallinity of CBZ
in the extruded formulation.
5.3.2. Hot Melt Extrusion (HME)
CBZ and Klucel

TM

ELF hydroxypropylcellulose (HPC) polymers were sieved using ASTM #35

mesh. Physical mixtures of 20-50% w/w CBZ with Klucel TM ELF (Table 5-1) were mixed
using a V-Shell blender for 10 minutes. Three samples from each physical mixture were
analyzed for blend drug content and uniformity. The resulting blends were extruded with or
without P-CO2 injection using a twin-screw extruder (16 mm Prism EuroLab, ThermoFisher
Scientific) at screw speeds of 100-120 rpm and temperature range 110–130°C. P-CO2 was
injected at 125-175 psi into the extruder using a high-pressure regulator connected with flexible
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stainless steel, armor-cased hosing. The other end of the hose was connected to the injection port
seating on segment 6 of the extruder barrel. All of the extrudates were milled and sieved through
ASTM #35 mesh using a comminuting mill (Fitzpatrick, Model L1A).

Table 5-1: CBZ formulation composition of HME
CO2 injection

CO2 Pressure

Zone

(PSI)

80

-

-

20

80

Zone 6

175

C3

30

70

-

-

C4

30

70

Zone 6

150

C5

40

60

-

-

C6

40

60

Zone 6

150

C7

50

50

-

-

C8

50

50

Zone 6

125

Formulation

CBZ (%)

KlucelTM ELF(%)

C1

20

C2
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5.3.3. Density
Bulk and tap density were performed for all extrudates as well as for physical mixtures. True
density was measured using Micromeritics AccuPyc II1340 Gas Pycnometer, where the samples
were measured by helium displacement methods. The principle of this operation is to seal the
known volume sample in the instrument compartment then the helium as an inert gas is inserted,
and then helium molecules rapidly fill the pores; only the solid phase of the sample displaces the
gas. Dividing this volume into the sample weight gives the gas displacement density.
5.3.4. Surface Area
Surface areas of all milled extrudates with and without CO2 injection were evaluated using
Micromeritics, Gemini VII. 2-3 gm. of milled extrudates were placed in the sampling tube and
the reference sample was used to calibrate the analysis to produce continued accuracy of results.
Before analysis start, each sample was placed under vacuum to remove the moisture. The
nitrogen adsorption-desorption isotherms of the samples were obtained at liquid nitrogen
temperature (-195 Co). The specific surface area of the samples was obtained by means of the
standard method of Brunauer Emmett-Teller (BET).
5.3.5. Scanning Electron Microscopy (SEM)
Scanning Electron Microscopy (SEM) was used to evaluate the morphology of the extrudates
with and without P-CO2 injection. Samples were mounted on adhesive carbon pads placed on
aluminum then they sputter coated with gold using a Hummer® 6.2 sputtering system (Anatech
LTD, Springfield, VA) in a high vacuum evaporator. A JEOL JSM-5600 scanning electron
microscope operating at an accelerating voltage of 10kV was used for imaging.
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5.3.6. High-Performance Liquid Chromatography (HPLC)
All samples analyses were performed on a Waters HPLC and Empower software was used to
analyze the data. HPLC system consists of Waters e2695 separation Module and Waters 2489
UV/Visible detector (Waters Technologies Corporation, 34 Maple St., Milford, MA 0157). A
Phenomenex luna C18 (250 mm × 4.6 mm, 5µ) coulmn was used. The mobile phase constituted
of 65:35:0.1 (%v/v) Methanol: Water: Acetic acid at flow rate of 1 mL/ min and injection
volume of 20 µl. The UV detector wavelength for CBZ detection was set at 285 nm.

5.3.7. In-Vitro Drug Release
Extrudates equivalent to 50 mg CBZ were filled in HPMC capsules. The in vitro drug release
profiles were performed using a USP type II dissolution apparatus. The dissolution medium was
900 mL water and, was maintained at 37 oC with paddle rotation speed of 100 rpm. A sample
volume of 2 mL was taken at time points 10, 20, 30, 45, 60, 90 and 120 min., filtered and
analyzed using HPLC and 2 mL of fresh dissolution medium were added back to the dissolution
vessel at each time point to maintain the dissolution medium volume.
To understand the CBZ release results, data observed from in-vitro release study were used to
calculate Dissolution Efficiency (DE) and Mean Dissolution Time (MDT) of the all formulation
as a model independent method to compare the drug release profile of the extrudates with and
without P-CO2 injection. KinetDS 3.0 software was used to calculate DE and MDT [60] using the
following equations.
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𝑡

∫ 𝑄 𝑑𝑡

𝐷𝐸 = 𝑄 0

100 ×100

× 100

(Equation 5-1)

Where:
Q – amount (%) of drug substance released at the time t
t- time
Q100 – maximum amount of drug released (= 100%)

𝑀𝐷𝑇 =

𝐴𝑉
∑𝑛
𝑗=1 𝑡𝑗 ×∆𝑄𝑗

(Equation 5-2)

∑𝑛
𝑗=1 ∆𝑄𝑗

Where:
ΔQ = Q(t) - Q(t-1)
t AV
j = (ti + ti-1)/2
n – amount of time points
Similarity factors (f2) were also calculated using (equation 5-3) to evaluate the effect of P-CO2 on
the drug release.
2 −0.5

𝑓2 = 50 × log {[1 + (1/𝑛) ∑𝑛𝑗=1 𝑊𝑗 |𝑅𝑗 − 𝑇𝑗 | ]
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× 100}

(Equation 5-3)

5.4. Results and Discussion
5.4.1. Thermal Analysis
TGA data of CBZ, KlucelTM ELF and physical mixture did not show any sign of degradation
until reaching approximately 250 oC and 300 oC for CBZ and KlucelTM ELF respectively. At
those temperatures, the samples weight decreased by elevation the temperature. These results
indicate that all prepared formulations were stable under the utilized processing temperatures
(Figure 5-2). Additionally, TGA data also showed that KlucelTM ELF exhibited around 3%

Weight % (%)

moisture uptake.

Temperature (oC)

Figure 5-2: TGA thermogram of carbamazepine (CBZ) and Klucel
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TM

ELF.

DSC analysis was performed to determine the miscibility of CBZ/KlucelTM ELF in different drug
load as well as evaluate the physical state of the CBZ in all extrudates prepared in this study. The
DSC thermogram showed the CBZ endotherm melting peaks at 190oC. On the other hand, the
physical mixtures showed a slight melting point depression of CBZ in the presence of the Klucel
TM

ELF, indicating its miscibility in the polymeric matrix (Figure 5-3). DSC data of the

extrudates exhibit the disappearance of the endothermic melting peak of CBZ for all extrudates
with and without P-CO2 injection except for C7 and C8. The absence of the CBZ endothermic

Heat Flow Endo UP (mW)

melting peak indicates the formation of amorphous solid dispersion (Figure 5-4).

Temperature (oC)

Figure 5-3: DSC thermogram of CBZ/ Klucel TM ELF physical mixtures showing the
drug- polymer miscibility at different drug loading.
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Heat Flow Endo UP (mW)

Temperature (oC)

Figure 5-4: DSC thermogram of 20%, 30%, 40% and 50% of CBZ/ Klucel TM ELF
extrudates with and without P-CO2 injection as well as pure CBZ.
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DSC data are also used to determine the % crystallinity of CBZ in C7 and C8 formulation using
the following equation

Crystallinity (%) = [ΔHExtrudate/ (ΔHCBZ × w %)] ×100

(Equation 5-4)

The DSC thermogram (Figure 5-5) showed that ΔH of the CBZ is 102.402 J/g and the w% of the
formulations were calculated depending on the drug content results. There was no significant

Heat Flow Endo UP (mW)

different between the % crystallinity of C7 and C8 (approximately 23%).

Temperature (oC)

Figure 5-5: DSC thermogram showing the ΔH values of 50% CBZ/ Klucel TM ELF
extrudates with and without P-CO2 injection as well as pure CBZ.

64

5.4.2. Hot Melt Extrusion (HME)
The extrusion processing parameters were set depending on the TGA results and the feasibility
and processability of the physical mixtures used in this study (Table 5-2). The twin-screw
extruder (16 mm Prism EuroLab, ThermoFisher Scientific) consists of ten segments and an
extrusion die. The screw configuration used in this study was Thermo Fisher Scientific standard
cofiguration which consists of four conveying segments and three mixing zones and all of the
injections were made through the injection port at the conveying zones of the screw
configuration. The carbon dioxide was injected in the extruder using a high-pressure regulator
connected with flexible stainless steel hose with armor casing. The other end of the hose was
connected to the four-way connection, fitted with a pressure gauge, bleed valve, check valve
(ball type for unidirectional flow of gas), with the later being connected to the injection port
seating on the extruder in barrel segment 6. Before the injection of P-CO2, all the extruder barrel
segments were filled with melted physical mixture to form melt seal and prevent the escaping of
CO2 from the feeding zone.
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Table 5-2: Processing parameters for hot melt extrusion process of C1-C8

Formulation

Extrusion Temp. (oC)

Screw Speed (rpm)

Torque (Nm)

C1

130

100

9

C2

130

100

7

C3

110

100

8-9

C4

110

100

6-8

C5

110

100

9-12

C6

110

100

9-10

C7

120

100

14-18

C8

120

100

8
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The exrudates without P-CO2 were dense and opaque, also having plastic morphology. On the
other hand, the morphology of all extudates processed with P-CO2 were changed to a foam like
structure (Figure 5-6) due to the carbon dioxide expansion exiting at the terminal end of the die.
The torque values of the extruder were decreased with the formulations processed with P-CO2
injection compared with the formulations without P-CO2 injection. This observation indicating
the plasticization effect of carbon dioxide and prove the decrease in the glass transition
temperature (Tg) of the blends processed with P-CO2.

Without CO2 injection

With CO2 injection

Figure 5-6: Photographic picture of CBZ /Klucel
P-CO2 injection.

67

TM

ELF extrudates with and without

The milling efficiency of formulations C2, C4, C6 and C8 were higher than the milling efficiency
of formulations C1, C3, C5 and C7. This result was concluded by the torque values of the
comminuting mill (Fitzpatrick, Model L1A).
5.4.3. Density
True density was evaluated using AccuPyc II1340, Micromeritics to all formulations, C1-C8.
There are negligible differences in the true density values of the extrudates with and without CO2
injection indicating no chemical change in the nature of the CBZ/KlucelTM. This result confirmed
that CO2 is an inert material and there is no interaction between CO2 and CBZ/KlucelTM
formulations. On the other hand, there was a decrease in the bulk and tap densities of the
formulations processed with CO2 injection (C2, C4, C6, C8) than those processed without CO2
(C1, C3, C5, C7) as a direct result of the formation of foamy like structure extudates in case of
CO2 injection as well as increase in the pore size of those extrudates. Table 5-3 displayed that the
bulk density of formulations (C2, C4, C6, C8) are lower than formulations (C1, C3, C5, C7) by 2343%, While, the tap density lowered by 16- 35%.

68

Table 5-3: Bulk and tap density of CBZ /KlucelTM ELF with and without P-CO2 injection ±
Standard deviation n=3
Sample Name

Bulk Density

Tap Density

20% CBZ/ELF PM

0.436 ± 0.013

0.578 ± 0.008

C1

0.356 ± 0.009

0.470 ± 0.006

C2

0.205 ± 0.008

0.307 ± 0.005

30% CBZ/ELF PM

0.335 ± 0.001

0.554 ± 0.032

C3

0.377 ± 0.011

0.490 ± 0.002

C4

0.262 ± .001

0.367 ± 0.001

40% CBZ/ELF PM

0.452 ± 0.003

0.637 ± 0.004

C5

0.469 ± 0.003

0.616 ± 0.011

C6

0.325 ± 0.006

0.449 ± 0.010

50% CBZ/ELF PM

0.484 ± 0.008

0.715 ± 0.016

C7

0.507 ± 0.011

0.638 ± 0.017

C8

0.391± 0.006

0.537 ± .016
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5.4.4. Surface area
Surface area is considered as one of the important factors that affect the dissolution profiles of
any drug. It was observed that increasing the surface area of any formulation will result in more
contact with the dissolution medium and hence increase the in-vitro drug release. Moreover, the
drug absorption will increase which enhance the drug bioavailability. Gemini VII, Micromeritics
was used to measure the surface area of C1-C8. Table 5-4 shows the surface area and the
calculated % porosity for C1-C8 formulations. The % porosity was calculated using the following
equation:

𝐵𝑢𝑙𝑘 𝐷𝑒𝑛𝑖𝑠𝑡𝑦

% 𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 = (1 − 𝑇𝑟𝑢𝑒 𝐷𝑒𝑛𝑠𝑖𝑡𝑦) × 100

(Equation 5-5)

Formulations C2, C4, C6 and C8 exhibited higher surface area as well as higher % porosity
compared to formulations C1, C3, C5 and C7. This is considered as a direct result of
morphological change of C2, C4, C6 and C8 due to the injection of P-CO2 during the HME
process.
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Table 5-4: Surface area and % porosity of different drug loading CBZ /KlucelTM ELF with
and without P-CO2
Sample Name

Surface Area (m2/gm)

% Porosity

C1

0.261

71

C2

0.394

84

C3

0.350

70

C4

0.493

79

C5

0.412

62

C6

0.489

74

C7

0.445

59

C8

0.523

68

71

5.4.5. Scanning electron microscopy (SEM)
SEM images were used to evaluate the morphological surface of the extrudates C1-C8. Figure 5-7
presented the differences in the morphological characterization of formulations C1, C3, C5, C7
(without P-CO2 injection) and formulations C2, C4, C6, C8 (with P-CO2 injection) by using
longitudinal section (LS) of the extrudate samples. The images confirmed that all formulations
processed with P-CO2 were porous that is one of the foam like structure characterization. While,
the other extrudates formulated without P-CO2 were dense and no evidence of any pores in their
extrudates structure was observed.
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a

b

Figure 5-7: SEM image of LS of CBZ /Klucel
injection, b) with P-CO2 injection.
73

TM

ELF extrudates a) without P-CO2

5.4.6. CBZ Drug Content and Uniformity
HPLC analysis was used to evaluate the drug content uniformity of all CBZ/Klucel TM ELF
extrudates and physical mixtures with different drug loading that were used in this study. The
results showed that, all physical mixture blends and extrudates were in an acceptable range of
(93%-101%). With more focus on the formulations processed with P-CO2, the drug content
results indicating more precision and uniformity of the drug in the polymer carrier (97%-101
%.). These results may give more additional advantage of the carbon dioxide as a drug content
uniformity enhancer.
5.4.7. In-Vitro Drug Release
As mentioned earlier, the in-vitro drug release profile is important for the prediction of the
absorption and the bioavailability of any API. In many published reports, changing the
morphology of the hot melt extrudates as well as increasing the surface area will enhance the
release profile of the API. In this study, all the formulations processed with P-CO2 exerted an
enhancement of CBZ release in water at 37oC compared to other formulations without P-CO2
and the pure CBZ (Figure 5-8). Moreover, the CBZ release profile of the 50% drug load
formulations processed with P-CO2 injection was less than 20%, 30% and 40% drug loading
which have a complete drug release within 2 hours. While, the drug release profile of different
drug loading formulations processed without P-CO2 injection results showed that 20% , 30%,
40% and 50% having 90%, 86%, 80% and 73% CBZ drug release respectively. From these
results, it can be concluded that 40% drug load is the saturation point of the CBZ/ Klucel

TM

.

Because of reaching this point, 50% drug loading formulations C7 and C8 the CBZ dispersed as a
mixture of amorphous and crystalline state.
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20% CRZ/ KlucelTM ELF
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With out CO2

With CO2

Figure 5-8-a: Dissolution profiles of 20% CBZ/KlucelTM ELF extrudates with and without
P-CO2 injection and pure CBZ (Water, USP App II, 100 rpm and 37oC).
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30% CBZ/KlucelTM ELF
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% Drug Release
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Figure 5-8-b: Dissolution profiles of 30% CBZ/KlucelTM ELF extrudates with and
without P-CO2 injection and pure CBZ (Water, USP App II, 100 rpm and 37oC).
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40% CBZ/KlucelTM ELF
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Figure 5-8-c: Dissolution profiles of 40% CBZ/KlucelTM ELF extrudates with and
without P-CO2 injection and pure CBZ (Water, USP App II, 100 rpm and 37oC).
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50% CBZ/KlucelTM ELF
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% Drug Release
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Figure 5-8-d: Dissolution profiles of 50% CBZ/KlucelTM ELF extrudates with and
without P-CO2 injection and pure CBZ (Water, USP App II, 100 rpm and 37oC).
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f2 values were calculated to compare the formulations of the same drug loading with and without
P-CO2 injection. The results showed that all f2 values were less than 50 (Table 5-5) indicating
that dissolution profiles were not similar. Furthermore, 30% and 40% drug loading formulation
exhibited significant dissimilarity with f2 values of 27.96 and 28.18 respectively.
Models independent approaches were used to understand and compare the drug dissolution
profile of the same drug loading formulation with and without P-CO2 injection. The dissolution
efficiency of all formulations processed with P-CO2 were increased compared with the same drug
loading formulation processed without P-CO2 (Table 5-6). On the other hand, the mean
dissolution time of all formulations processed with P-CO2 were decreased compared with the
same drug loading formulation processed without P-CO2 (Table 5-6). C4 and C6 formulation
observed the maximum DE value of 70.577 % and 66.374% and the lowest MDT of 35.308 and
37.987 minutes respectively. Based on f2, DE and MDT results it was confirmed that the
injection of P-CO2 through HME process increased the CBZ/klucelTM ELF solid dispersion drug
load capacity up to 20% more than the regular HME process.
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Table 5-5: Similarity factor of 20%, 30%, 40% and 50% CBZ /KlucelTM ELF formulations
with and without P-CO2
Formulation

f2

Similarity Status

C1 and C2

43.967

Dissimilar

C3 and C4

27.960

Dissimilar

C5 and C6

28.183

Dissimilar

C7 and C8

43.744

Dissimilar

Table 5-6: Dissolution efficiency and the mean dissolution time of 20%, 30%, 40% and
50% CBZ /KlucelTM ELF formulations with and without P-CO2
Without P-CO2 injection

20% CRZ
/KlucelTM ELF
30% CRZ
/KlucelTM ELF
40% CRZ
/KlucelTM ELF
50% CRZ
/KlucelTM ELF

DE*

With P-CO2 injection

DE*

MDT**

DE*

MDT**

50.276

53.291

61.800

45.837

45.626

56.968

70.577

35.308

40.941

59.296

66..374

37.987

39.907

54.600

52.950

51.292

Dissolution efficiency

MDT** Mean Dissolution Time
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5.5. Conclusion
Carbamazepine (CBZ) polymeric dispersions can be prepared using the novel technique of
linking HME with P-CO2 injection. The resulted extrudates showed an increase in porosity and
changed the macroscopic morphology to a foam-like structure due to expansion of the carbon
dioxide at the extrusion die. HME processing assisted with P-CO2 increased the drug loading
capability of CBZ in KlucelTM ELF polymeric matrix as well as optimized CBZ drug- release
profiles. These processed properties of materials would provide numerous benefits during
manufacturing of various solid dosage forms.
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CHAPTER VI
Dissolution Enhancement of the Psychoactive Natural Product- Piperine Using Hot Melt
Extrusion Techniques
6.1. Introduction
Oral drug delivery is considered as the simplest and easiest route of the drug administration[61,
62]. Oral bioavailability is mainly affected by drug solubility, permeability [63-66] and first pass
metabolism [67]. In fact, most of the new APIs have low water solubility with low release
profiles after oral administration. The biggest challenge in the pharmaceutical industry was to
enhance the solubility, and the permeability of those drugs as key factors to improve their
bioavailability. There are many techniques which have been used to improve the drug water
solubility and release profile, and solid dispersions are considered to be the most successful
techniques. There are two main solid dispersions manufacturing methods ; the melting methods
such as hot melt extrusion; and solvent evaporation methods such as spray drying [15]. Hot melt
extrusion (HME) is one of the most commonly used techniques to enhance the solubility and oral
bioavailability of poorly soluble drugs as a beneficial technique for solid dispersion. It involves
simple dispersion of poorly water soluble API in an inert carrier (polymer), where the drug could
exist in amorphous or crystalline state. . There are many advantages of using HME due to the
speed and the continuous manufacturing process. Moreover, since no solvent is required, it is
considered to be a green method for enhancement of the solubility and oral bioavailability of
poorly soluble drugs. Depending on the polymeric carrier; hot melt extrusion can be also used for
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other purposes such as taste masking, controlling or modifying drug release and stabilizing the
active pharmaceutical ingredient.
Piperine (1-piperoylpiperidine) (Figure 6-1) is a crystalline pungent alkaloid isolated from black
pepper (Piper nigrum), long pepper (Piper longum) and other pepper species (family:
Piperaceae) [68-70]. Piperine is a poorly water soluble compound with a melting point at 135 oC.
It has been extensively used in folk medicine in many Asian countries [69] and various studies
have focused on investigating the pharmacological effects of piperine. Recently, it was reported
as an anti-inflammatory, analgesic [71] [72], anti-depressant [73], cytoprotective, anti-leukemic
and anti-oxidant agent [68, 74]. Furthermore, piperine significantly improves spatial memory and
neurodegeneration in an Alzheimer’s disease animal model [75]. Furthermore, piperine was
reported to be a bioavailability enhancer [76]. Pattanaik et al investigated that 20 mg oral
piperine can enhance the bioavailability of phenytoin and carbamazepine by increasing their
plasma dug concentration[77, 78]. Atal et al proved that piperine is a potent inhibitor of the drug
metabolism [79]. Literatures reports show that piperine acts as a metabolic inhibitor which
inhibits the drug metabolizing enzyme such as CYP3A4, CYP1B1, CYP1B2 and CYP2E1. [76]
[80] [81]. This finding gave the interest to incorporate the piperine with the anti-cancer acetyl11-keto-ß-boswellic acid to increase its bioavailability and therapeutic efficacy [82].
Additionally, piperine modulate the permeability characteristics to increase the drug absorption
through the cell membrane by increasing the vasodilation of the GIT membrane [70, 83]. Being a
natural product, piperine had many advantages compared to other chemical entities such as low
coast due to availability from plant material using easy and well known extraction and isolation
methods [84]. Moreover, it is safe to use.
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Figure 6-1: Chemical structure of piperine.

In the current study, the main goals were to enhance the solubility and the permeability of
piperine in order to enhance its bioavailability and therapeutic efficacy. Three polymeric carriers
Soluplus®, polyvinylpyrrolidone-co-vinylacetate 64 (Kollidon® VA 64) and Eudragit ® EPO were
used via the hot melt extrusion process to accomplish these goals.
6.2. Materials
Piperine was purchased from Sigma-Aldrich (Milwaukee, WI 53233, USA), while Soluplus® and
Kollidon® VA 64 were obtained from BASF- SE (Ludwigshafen, Germany), Eudragit ® EPO was
received as a gift sample from Evonik Industries (Parsippany, NJ 07045, USA). All other
chemicals and reagents used in the present study were of analytical grade and obtained from
Fisher Scientific (Fair Lawn, NJ 07410 USA).
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6.3. Methods
6.3.1. Thermogravimetric Analysis (TGA)
TGA analysis were performed for piperine, Soluplus®, Kollidon® VA 64 and Eudragit

®

EPO to

evaluate their stability at the extrusion temperatures using a Perkin Elmer Pyris 1 TGA equipped
with Pyris manager software (PerkinElmer Life and Analytical Sciences, 710 Bridgeport Ave.,
Connecticut, USA). Approximately 10-15 mg of piperine, polymers as well as physical mixtures
were heated from 30°C to 300 °C at heating rate of 20°C/min.
6.3.2. Differential Scanning Calorimetry (DSC)
DSC studies were obtained using Perkin Elmer Pyris 1 DSC equipped with Pyris Manager
Software (PerkinElmer Life and Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA).
Approximately 2-4 mg of piperine, physical mixtures or extrudates were heated from 30°C to
200°C at a heating rate of 10°C/min.
6.3.3. Hot Melt Extrusion (HME)
Piperine 10–40% w/w and Eudragit® EPO, Kollidon® VA 64 or Soluplus® (Table 6-1) were
mixed using a V-shell blender (Patrtreson-Kelley Twin Shell Dry Blender) for 10 minutes. The
resulting physical mixture blends were extruded using a twin-screw extruder (Process 11 Twin
Screw Extruder, ThermoFisher Scientific) at the screw speed of 150 rpm at a temperature range
of 100–130°C. All extrudates were milled and sieved through an ASTM #35 mesh to obtain a
uniform particle size.
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Table 6-1: Piperine formulation composition of HME
Piperine (PIP)

Eudragit ® PE

Soluplus ®

Kollidon® VA

(%)

(%)

(%)

(%)

P1

10

90

-

-

P2

20

80

-

-

P3

40

60

-

-

P4

10

-

90

-

P5

20

-

80

-

P6

40

-

60

-

P7

10

-

-

90

P8

20

-

-

80

P9

40

-

-

60

Formulation
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6.3.4. Scanning Electron Microscopy (SEM)
The morphology and physical state of the extrudates were evaluated using SEM analysis.
Samples were mounted on adhesive carbon pads placed on aluminum and were sputter coated
with gold using a Hummer® 6.2 sputtering system (Anatech LTD, Springfield, VA) in a high
vacuum evaporator. A JEOL JSM-5600 scanning electron microscope (SEM) operating at an
accelerating voltage of 10kV was used for imaging.
6.3.5. Fourier transforms infrared spectroscopy (FTIR)
FTIR spectra of piperine, polymeric carriers, physical mixtures as well as extrudates were
performed using Agilent Cary 630 FTIR spectrometer equipped with a DTGS detector. 2-4 mg
sample was placed directly on ATR and the scanning range was 400 - 4000 cm−1 and the
resolution was 1 cm−1.
6.3.6. High Performance Liquid Chromatography (HPLC)
HPLC analyses were performed on all samples for piperine content using a Waters HPLC
equipped with Empower software to analyze the data. HPLC consisted of a Waters e2695
separation Module and Waters 2489 UV/Visible detector, (Waters Technologies Corporation, 34
Maple St., Milford, MA 0157). The column used was Phenomenex Luna C18 (5µ, 250 mm × 4.6
mm). The mobile phase consisted of a mixture of 0.1% ortho phosphoric acid and acetonitrile
(45:55 v/v) with a flow rate of 1.2 mL/min and 20µL injection volume. The column temperature
was 35oC (±2). The UV detector wavelength for piperine detection was set at λmax 262 nm [85].
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6.3.7. Solubility test
The solubility was determined at pH 1.2, 5 (water), and 6.8 for formulations P4 - P9 as well as
pure piperine. Sample equivalents to approximately 100 mg of piperine based on the drug load of
each formulation were shaken in 20 mL scintillation vials containing 10 mL of tested pH
solution. The samples were shaken at 80 rpm and at 25oC using Thermo Scientific Precision
Reciprocal Shaking Bath. A sample volume of 1 mL was collected at time points 4, 10, 20 and 24
h. The samples were filtered and analyzed by HPLC, and 1 mL of the same pH solution was
added back to the scintillation vials to maintain the volume.
6.3.8. In-vitro Drug Release
A sample equivalent to 40 mg piperine of each extrudate as well as pure piperine were filled in
gelatin capsules and the in-vitro drug release profiles were run using a USP type II dissolution
apparatus. The used dissolution medium was 900 mL 0.1 N HCl maintained at 37 o C. A sample
volume of 2 mL was taken at time points 10, 20, 30, 45, 60, 90, and 120 min. and was filtered
and analyzed using HPLC; then2 mL of fresh dissolution medium was added back to the
dissolution vessel at each time point to maintain the volume.
6.3.9. Ex vivo permeability model (non-everted intestinal sac)
The permeability studies were performed for the most promising formulation (P4) and pure
piperine was used as the control. Non-everted intestinal sacs of male Sprague- Dawley rats,
weighing approximately 200 -250 g, were provided from Charles river (Wilmington MA 01887,
USA). Sacs of 4-5 cm in length were prepared. Each sac was filled with 0.5 mL of incubated
Krebs-Ringer bicarbonate phosphate buffer, pH 7.4 with piperine 5mg/ml. Each non-everted sac
was placed in 25mL beaker containing 5mL of Krebs-Ringer bicarbonate phosphate buffer, pH
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7.4. A sample volume of 1 ml was taken from the solution outside the sac at time points of 0, 20,
50, 80 and 120 minutes. The samples were filtered and analyzed for the content using HPLC.
Fresh Krebs-Ringer buffer (1 mL) was added back to the beaker at each time point to maintain
the volume. Cumulative dissolution profiles were calculated.
6.4. Results and discussion:
6.4.1. Pre-formulation Studies
Under all utilized processing temperatures, TGA data showed no decrease in sample weight
which indicate that all formulations in the study were stable under all applied extrusion
temperatures.
DSC data showed the endothermic crystalline melting peak at 135oC for pure piperine and all the
physical mixture samples (Figure 6-2). Alternatively, all the extrudates showed absence of
crystalline melting peaks in DSC data (Figure 6-3).
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Heat Flow Endo UP (mW)

Temperature (oC)

Figure 6-2: DSC thermogram of 10%, 20% and 40% of PIP/ Eudragit ® PEO, PIP/
Soluplus® and PIP/ Kollidon® VA 64 physical mixtures.
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Heat Flow Endo UP (mW)

Temperature (oC)

Figure 6-3: DSC thermogram of 10%, 20% and 40% of Piperine/ Eudragit ® PEO,
Piperine/ Soluplus® and PIP/ Kollidon® VA 64 extrudates.
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6.4.2. Hot Melt Extrusion (HME)
HME process was carried out using (Process 11 Twin Screw Extruder, fromThermo Fisher
Scientific. The Thermo Fisher standard screw configuration was used in this study. The screw
configuration consists of four conveying zones and three mixing zones (Figure 6-4). The hot melt
extrusion processing conditions such as extrusion temperature, screw speed and the torque values
are showen in (Table 6-2). The resulting extrudates were transparent, greenish yellow and brittle
extrudates except for P3 (40% piperine0/ Eudragit® EPO) which was opaque. This observation
can be explained by the fact that 40% of drug load exceeded the Eudragit ® EPO carrier capacity
allowing the extudate to mimic the appearance of the piperine only. All extrudates were milled
using coffee grinder and sieved through an ASTM #35 mesh to obtain a uniform particle size.
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Figure 6-4: Standard screw configuration of Process 11 Twin Screw
Extruder, Thermo Fisher Scientific.
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Table 6-2: Processing parameters for hot melt extrusion of PIP/ Eudragit ® PEO, PIP/
Soluplus® and PIP/ Kollidon® VA formulations
Processing
Formulation

Temperature
(oC)

Screw Speed

Torque

Extrudate

(rpm)

(Nm)

Image

P1

110

150

6-7

P2

110

150

4-5

P3

110

150

3

P4

120

150

7-8

P5

120

150

4-5

P6

120

150

3-4

P7

130

150

7-8

P8

130

150

3-4

P9

130

150

3-4
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6.4.3. Scanning electron microscopy (SEM)
SEM images showed absence of crystals in 10% w/w piperine/Soluplus® indicating that piperine
was dispersed in the Soluplus® polymer carrier as an amorphous form. This may help to enhance
the solubility and the bioavailability of this formulation. However, crystals were evident in the
other piperine/ Soluplus® formulations with different ratios (Figure 6-5). In addition, SEM
images demonstrated crystals in Kollidon® VA 64 and Eudragit

®

EPO formulation (Figure 6-6).

These results are not consistent with the DSC results that showed absence of the piperine
crystalline peak in the resulting extrudates. This observation be explained the fact that all
polymers used in this study i.e., Eudragit® EPO, Kollidon® VA 64, and Soluplus® had a Tg
temperature of 45 oC, 101 oC and 70 oC respectively which are lower than the piperine melting
point. Due to this; the polymers used will soften before the melting temperature of piperine
allowing the piperine to solubilize in the polymer matrix and prevent the melting peak
appearance.
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a

b

c

®

Figure 6-5: SEM of extrudates: a) 10% w/w piperine/Soluplus , b) 20%
®

®

w/w piperine/Soluplus , c) 40% w/w piperine/Soluplus .
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a

b

Figure 6-6: SEM of extrudates: a) 20% piperine/Eudragit
®

20% piperine/Kollidon VA64.
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®

EPO, b)

6.4.4. Fourier transforms infrared spectroscopy (FTIR)
FTIR analysis was performed to evaluate any chemical or physical interaction between piperine
and the different polymeric carriers. Figure 6-7 shows the FTIR spectra of Soluplus and their
formulations, the physical mixture displays a sharp peak at 1623 cm-1, and this peak shifts to
approximately 1629 cm-1 for all Soluplus formulations confirmed the presence of hydrogen
bonding between piperine and Soluplus®. While, there were no shift observed in Eudragit® EPO
(Figure 6-8), and Kollidon® VA 64 formulations (Figure 6-9). The formation of hydrogen
bonding will increase the stability of the Soluplus solid dispersion formulations and prevent
recrystallization of piperine [15, 86, 87].
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Figure 6-7: FTIR spectra of Soluplus , piperine, 10% piperine /Soluplus ,
®

®

20% piperine /Soluplus , and 40% piperine /Soluplus extrudates.
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Figure 6-8: FTIR spectra of Eudragit EPO, piperine, 20% piperine / Eudragit
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Figure 6-9: FTIR spectra of Kollidon VA 64, piperine, 20% piperine / Kollidon
VA 64 physical mixture and extrudates.
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®

6.4.5. Solubility Evaluation
The shake- flask method was used to determine the piperine solubility at pH value at equilibrium
state [88].Solubility study was performed for formulations P4, P5, P6, P7, P8 and P9 using three
different solvents pH (1.2, 5 [(water)], and 6.8) to evaluate whether piperine solubility is pH
dependent or not. The pH did not have any effect on the solubility of piperine as there were slight
changes in the solubility values at pH 1.2 and 6.8 (Table 4-3). Furthermore, in formulations P4
P5, P6, P7, P8 and P9 water solubility of piperine increased more than 160, 45, 25, 20, 5 and 3
folds respectively compared to pure piperine solubility in water (Table 6-3). This significant
enhancement in the water solubility of piperine in P4 was due to the dispersion of piperine in its
amorphous state. Amorphous solid dispersion play a significant role in increasing the solubility
and the dissolution rate of poorly water soluble APIs [89-92]. In general, amorphous API is more
soluble than crystalline ones because of its higher effective surface area than the crystalline form
[93-95]. However, the main problem associated with amorphous API is its instability, which can
lead to recrystallization during storage as well as during dissolution [96]. In contrast, amorphous
solid dispersions are stable as the polymeric carrier prevent the API recrystallization [97].
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Table 6-3: Solubility of piperine and piperine formulation in water, pH 1.2 and 6.8
Solubility in pH

Solubility in Water

Solubility in pH 1.2

(mg/L)

(mg/L)

Piperine

1

0.9

0.9

P4

163

117

117

P5

47

39

45

P6

27

21

27

P7

20

18

17

P8

6

6

6

P9

3

3

3

Formulation
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6.8
(mg/L)

6.4.6. In-vitro Release Profiles
Dissolution studies demonstrated improvement in piperine drug release of 10% and 20% w/w
piperine/Soluplus® extrudates up to 95% and 74%, respectively (Figure 6-10). However, no
effect on piperine drug release profiles for other formulations was noted due to remaining of
piperine in the crystalline state. These results confirmed that the dispersion of piperine in
amorphous state plays a big role in enhancing the solubility [98] and drug release. Additionally,
it can be concluded that the maximum drug loading capacity of piperine in Soluplus to form
stabilized amorphous solid dispersion is approximately 10%. Soluplus® (Polyvinyl caprolactampolyvinyl acetate-polyethylene glycol graft copolymer) is a relatively new polymer designed
mainly for use in solid dispersion preparation ApIs [99]. It acts as a polymeric stabilizer and
solubilizing agent to improve the solubility and bioavailability of poor water soluble APIs [100102]. It is a good polymeric carrier candidate to prepare amorphous solid dispersions of many
poor water soluble APIs such as clotrimazole, carbamazepine, griseofulvine, and itraconazole by
improving their dissolution profiles as well as their intestinal absorption and bioavailability
[100]. In the recent study, Soluplus® was successfully used to prepare 10% piperine amorphous
solid dispersion with a significant increase in the piperine release profile.
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Figure 6-10: In-vitro release profiles of 10% w/w piperine/Soluplus®, 20% w/w
piperine/Soluplus®, 40% w/w piperine/Soluplus®, 20% piperine/Eudragit ® EPO,
20% piperine/Kollidon ® VA64 and pure piperine.
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6.4.7. Ex vivo permeability model (non-everted intestinal sac)
There are many in vivo, ex-vivo and in vitro assays used to evaluate the intestinal drug
permeability [103, 104]. These assays include perfusion, diffusion chambers, gut sac, cultured
cell and artificial membrain [105]. The results of a research investigation showed that there was a
good correlation between rat and human oral absorption. There are two types of rat intestinal sac
models which are used to evaluate the drug permeability, everted and non-everted sacs. Some
studies have been done to compare the permeability values of some APIs through both everted
and non-everted sacs and no significant difference was observed in the permeability results. In
this study, non everted rat intestinal sac model have been used to give an idea about the piperine
absorption in humans. The permeability study results (Figure 6-11) demonstrated the
enhancement in piperine absorption of 10% w/w piperine/Soluplus® up to 158.9 μg/5mL
compared to 1.4 μg/5mL in the case of pure piperine within 20 min. as a direct result of the
solubility improvement.
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Figure 6-11: Piperine absorption characteristics using jejunum non-everted sac under
normal physiological conditions (Krebs Ringer bicarbonate phosphate buffer, pH 7.4).
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6.5. Conclusion
HME was successfully used to enhance the solubility of the psychoactive natural product
piperine. The drug release profiles of 10% and 20% w/w piperine/Soluplus® hot melt extrudates
were significantly enhanced due to piperine in its amorphous state. In addition, the formation of
hydrogen bond between piperine and Soluplus® may inhibit drug recrystallization and assist in
the maintenance of the drug in its amorphous form thereby enabling good formulation stability.
Furthermore, a significant improvement in piperine permeability has been confirmed using a
non-everted rat intestinal sac. These results demonstrate that increase the absorption and
bioavailability of piperine are possibilities.
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